Skip to main content

Table 1 Summary characteristics of 2018 Harm Reduction Client Survey participants stratified by using alone in the last 7 days

From: Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada

Characteristics Did not use alone
(N = 100)
Used alone
(N = 314)
Total
(N = 414)
p value
n (%) n (%) n (%)
Age     0.16
19–29 16 (16.0%) 64 (20.4%) 80 (19.3%)  
30–39 22 (22.0%) 95 (30.3%) 117 (28.3%)  
40–49 30 (30.0%) 78 (24.8%) 108 (26.1%)  
> 50 32 (32.0%) 76 (24.2%) 108 (26.1%)  
Gendera     0.16
Woman 40 (40.0%) 104 (33.1%) 144 (34.8%)  
Man 56 (56.0%) 203 (64.6%) 259 (62.6%)  
Health authority     0.23
Fraser 38 (38.0%) 129 (41.1%) 167 (40.3%)  
Interior 19 (19.0%) 35 (11.1%) 54 (13.0%)  
Island 23 (23.0%) 68 (21.7%) 91 (22.0%)  
Northern 10 (10.0%) 50 (15.9%) 60 (14.5%)  
Vancouver Coastal (rural communities) 10 (10.0%) 32 (10.2%) 42 (10.1%)  
Urbanicity     0.74
Small urban/rural communities 26 (26.0%) 87 (27.7%) 113 (27.3%)  
Medium/large urban cities 74 (74.0%) 227 (72.3%) 301 (72.7%)  
Currently regularly housed     < 0.01
Yes 74 (74.0%) 186 (59.2%) 260 (62.8%)  
No 24 (24.0%) 118 (37.6%) 142 (34.3%)  
Currently employed     0.19
Yes 23 (23.0%) 53 (16.9%) 76 (18.4%)  
No 75 (75.0%) 250 (79.6%) 325 (78.5%)  
Naloxone kit possession     0.61
Yes 66 (66.0%) 213 (67.8%) 279 (67.4%)  
No 30 (30.0%) 85 (27.1%) 115 (27.8%)  
Preferred drug use method     0.87
Injection 32 (32.0%) 108 (34.4%) 140 (33.8%)  
Non-injectionb 59 (59.0%) 191 (60.8%) 250 (60.4%)  
Opioid use (last 7 days)c     0.04
Yes 60 (60.0%) 230 (73.2%) 290 (70.0%)  
No 36 (36.0%) 83 (26.4%) 119 (28.7%)  
Crystal meth use (last 7 days)     < 0.01
Yes 61 (61.0%) 241 (76.8%) 302 (72.9%)  
No 35 (35.0%) 72 (22.9%) 107 (25.8%)  
Crack/cocaine use (last 7 days)     0.01
Yes 26 (26.0%) 130 (41.4%) 156 (37.7%)  
No 70 (70.0%) 183 (58.3%) 253 (61.1%)  
Benzodiazepine use (last 7 days)     0.29
Yes 10 (10.0%) 46 (14.6%) 56 (13.5%)  
No 86 (86.0%) 267 (85.0%) 353 (85.3%)  
Alcohol use (last 7 days)     0.15
Yes 35 (35.0%) 140 (44.6%) 175 (42.3%)  
No 61 (61.0%) 173 (55.1%) 234 (56.5%)  
Polysubstance use (last 7 days)d     < 0.01
Yes 52 (52.0%) 215 (68.5%) 267 (64.5%)  
No 44 (44.0%) 98 (31.2%) 142 (34.3%)  
Experienced an opioid or stimulant overdose (last 6 months)     0.03
Yes 15 (15.0%) 72 (22.9%) 93 (22.5%)  
No 78 (78.0%) 194 (61.8%) 266 (64.3%)  
  1. Missing values account for percentages which do not add up to 100% or total numbers that do not add up to 414
  2. aOther genders reported included being a trans man, trans woman, or gender non-conforming which are not shown here due to small sample size (n = 9)
  3. bNon-injection methods included smoking/inhaling/snorting (56.5%, n = 234) and other methods (3.9%, n = 16)
  4. cOpioids included heroin, fentanyl, morphine, hydromorphone (Dilaudid), methadone, and oxycodone
  5. dPolysubstance use was defined as concurrent use of opioids & stimulants, opioids & benzodiazepines, or stimulants & benzodiazepines